InvestorsHub Logo
Followers 59
Posts 2267
Boards Moderated 0
Alias Born 02/13/2016

Re: None

Tuesday, 02/13/2018 11:11:58 AM

Tuesday, February 13, 2018 11:11:58 AM

Post# of 3283
They posted a new Pozi trial yesterday
A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

It's a dose finding study in combination with Kadcyla.

It is similar in design to a trial recently reported by Puma combining Neratinib with Kadcyla